Læknaneminn - 01.04.1988, Side 20

12. ) Dinarello, C.A.:Interleukin-l
and the pathogenesis of the acute phase
response. N. Engl. J. Med.
1984;311:1413-1418.
13. ) Beutler, B. Cerami,
A.:Cachectin and tumor necrosis factor
as two sides of the same biological coin.
Nature 1986;320:584-588.
14. ) Gabuzda, D.H., og Hirsch,
M.S.:Neurologic manifestations of
infection with Human
Intmunodeficiency Virus. Clinical
features and pathogenesis. Review.
Ann. Intem. Med. 1987;107:383-391.
15.) Grant, I. et akEvidence for
early central nervous system
involvement in the Acquired
Immunodeficiency Syndrome (AIDS)
and other Human Immunodeficyecy
Virus (HIV) infections. Studies with
neuropsychologic testing and magnetic
resonance imaging. Ann. Intern. Med.
1987;107:828-836.
16. ) Gurney, M.E.,Heinrich,
S.P.,Lee, M.R., Yin, H-S:Molecular
cloning and expression of neuroleukin,
a neurotrophic factor for spinal and
sensory neurons. Science
1986;234:566-574.
17. ) Fischl, M.A.,Richman,
D.D.,Grieco, M.H., the AZT
collaborative working group et al:The
efficacy og azidothymidine (AZT) in
the treatment of patients with AIDS and
AIDS-related complex. A double-
blind, placebo-controlled trial. N. Engl.
J. Med. 1987;317:185-191.
18. ) Richman, D.D.,Fischl,
M.A.,Grieco, M.H., the AZT
collaborative working group et al:The
toxicity of azidothymidine (AZT) in
the treatment of patients with AIDS and
AIDS-related complex. A double-
blind, placebo-controlled trial. N. Engl.
J. Med. 1987;317:192-197.
19. ) Wolf, F.D. et akEffect of
Zidovudine on serum human
immunodeficiency virus antigen levels
in symptom-free subjects. Lancet
1988;20.feb:373-376.
20. ) Ganser, A. et al:
Azidothymidine in the treatment of
AIDS.(Bréf til ritstjóra). N. Engl. J.
Med. 1988;318:250-251.
21. ) Hymes, K.B. et akThe effect of
Azidothymidine on HlV-related
thrombocytopenia.(Bréf til ritsjóra). N.
Engl. JMed. 1988;318:516-517.
22. ) Dalgleish, A. G., Thomson,
B.J., Chanh, T.C., Malkovsky, M. og
Kennedy, R.C.:Neutralization of HIV
isolates by anti-idiotypic antibodies
which mimic the T4 (CD4) epitope: A
potential AIDS vaccine. Lancet
1987;7. nóv: 1047-1050.
23. ) Baba,M. et aklnhibition of the
replication of Human Imntuno-
deficiency Virus by dextran sulfate and
heparin. LEuropean conference on
clinical aspects of HIV infection, 10-
ll.des 1987 (abstr.).
24. ) Bassetti,D. et akClinical
evaluation af an anti-Hl V drug (RS 47).
kEuropean conference on clinical
aspects of HIV infection, 10-11. des
1987 (abstr.).
25. ) Members of the AIDS-
Imuthiol French study group:
Treatment of ARC patients with
sodium diethylthiocarbamate (DTC,
Imuthiol). A multicentric, randomized,
double-blind, placebo controlled trial.
kEuropean conference on clinical
aspects of HIV infection, 10-11. des
1987 (abstr.).
26. ) Hörding, M. et aklmmuno-
modulation with Disulfiram in a
double-blindtrial with 15 HlV-positive
homosexual men. I:European
conference on clinical aspects of HIV
infection, 10-11. des 1987 (abstr.).
27. ) Faber, V. et aklnhibition of
HIV replication in vitro by fusidic acid.
Lancet 1987; 10.okt:827-828.
28. ) Barnes, D.M.:”On the shelf’
AIDS drug in clinical triakScience
1987;238:276.
29. ) Wybran, J. et aklmmunologic
properties af Methionine-Enkephalin,
and therapeutic implications in
AIDS.ARC and cancer. Ann. N.Y.
Acad. Sci.1987.108-114.
30. ) W y bran, J. et al: An open study
with Methionin Enkephalin in Aids-
Related Complex (ARC) and AIDS
patients:Immunological and clinical
results. I: European conference on
clinical aspects of HIV infection, 10-
11. des 1987 (abstr.).
31. ) Haverkos, H.W.:Factors
associated with the pathogenesis of
AIDS. J. Inf. Dis. 1987;156:251-257.
32. ) Wood, M.J., Geddes,
A.M.: Antiviral therapy. Lancet
1987;21.nóv:l 189-1191.
33. ) Crumpacker, C. et akRibavirin
treatment of the Acquired Immuno-
deficiency Syndrome (AIDS) and the
Acquired Immunodeficiency
Syndrome-Related-Complex. A Phase
I study shows transient clinical
improvement associated with
suppression of the Human Immuno-
deficiency Virus and enhanced
lymphocyte proliferation. Ann. Intern.
Med. 1987;107:664-674.
34. ) Hermans, P.E., Cockerill,
F.R.:Antiviral agents. MayoClin. Proc.
1987;62:1108-1115.
35. ) Gruters, R.A. et aklnter-
ference with HlV-induced syncytium
formation and viral infectivity by
inhibitors of trimming glucosidase.
Nature 1987;330:74-77.
36. ) Fischl, M.A. et akSafety and
efficacy of sulfamethoxazole and
trimethoprim chentoprophylaxis for
Pneumocystis carinii pneumonia in
AIDS. JAMA 1988;259:1185-1189.
37. ) Wybran.J., et akSuggestive
evidence formorphine and methionine-
enkephalin receptors like on normal
blood T lymphocytes. J. Immunol.
1979;123:1068-1070.
38. ) Weiss, Robin A.: Receptor
molecule blocks HIV. Nature
1988;331:15.
39. ) Fisher, R.A. et al: HIV
infection is blocked in vitro by
recombinant soluble CD4. Nature
1988;331:76-78.
40. ) Hussey, R.E.: A soluble CD4
protein selectively inhibits HIV
replication and syncytium formation.
Nature 1988;331:78-81.
41. ) Deen, C.K.: A soluble form of
18
LÆKNANEMINN 1/1988-41. árg.